Looking for 'external innovation,' Boehringer Ingelheim reserves $500M+ for new Shanghai hub
Now that Boehringer Ingelheim’s bet on contract manufacturing in China has paid off, the German drugmaker is anteing up more to get into the research …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
